市場調査レポート
商品コード
1092238

創薬向け人工知能 (AI) の世界市場:提供製品/サービス別 (ソフトウェア、サービス)・技術別 (機械学習、深層学習)・用途別 (心血管疾患、代謝性疾患、神経変性疾患)・エンドユーザー別 (製薬・バイオテクノロジー企業、CRO) の将来予測

Artificial Intelligence ( AI ) in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 193 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
創薬向け人工知能 (AI) の世界市場:提供製品/サービス別 (ソフトウェア、サービス)・技術別 (機械学習、深層学習)・用途別 (心血管疾患、代謝性疾患、神経変性疾患)・エンドユーザー別 (製薬・バイオテクノロジー企業、CRO) の将来予測
出版日: 2022年06月15日
発行: MarketsandMarkets
ページ情報: 英文 193 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要
CAGR 45.7%

世界の創薬向け人工知能 (AI) の市場規模は、2022年の6億米ドルから、2027年までに40億米ドルに達すると予測されています。

また、予測期間中のCAGRは45.7%となる見通しです。市場の主な促進要因として、創薬・開発コストの抑制や全体的な開発時間の短縮化ニーズ、クラウドベースのアプリケーション・サービスの普及などが挙げられます。一方、熟練労働者の不足などが今後の市場成長の妨げとなる可能性もあります。

提供製品/サービス別ではサービス分野が、技術別では機械学習技術が、エンドユーザー別では製薬・バイオテクノロジー企業が、最大のシェアを占めています。地域別に見ると、北米が最大の市場となっています。

当レポートでは、世界の創薬向け人工知能 (AI) の市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、市場動向の見通し、提供製品/サービス別・技術別・用途別・エンドユーザー別・地域別の詳細動向、市場競争の状態、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 分析方法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概略

  • イントロダクション
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
    • 課題
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • エコシステム
  • 技術分析
  • 価格分析
  • ビジネスモデル
  • 規則
  • 会議とウェビナー
  • ケーススタディ分析

第6章 創薬向け人工知能 (AI) 市場:提供製品/サービス別

  • イントロダクション
  • ソフトウェア
  • サービス

第7章 創薬向け人工知能 (AI) 市場:技術別

  • イントロダクション
  • 機械学習
    • 深層学習 (ディープラーニング)
    • 教師あり学習
    • 強化学習
    • 教師なし学習
    • その他の機械学習技術
  • その他の技術

第8章 創薬向け人工知能 (AI) 市場:用途別

  • イントロダクション
  • がん免疫
  • 神経変性疾患
  • 心血管疾患
  • 代謝性疾患
  • その他の用途

第9章 創薬向け人工知能 (AI) 市場:エンドユーザー別

  • イントロダクション
  • 製薬・バイオテクノロジー企業
  • CRO (医薬品開発業務受託機関)
  • 研究センター、教育・政府機関

第10章 創薬向け人工知能 (AI) 市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • 他の欧州諸国
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 他のアジア太平洋諸国
  • 他の国々 (RoW)

第11章 競合情勢

  • 概要
  • 主要企業の戦略/有力企業
  • 市場ランキング分析
  • 競合ベンチマーキング
  • 競合リーダーシップ・マッピング
  • 競合リーダーシップ・マッピング:新興企業/中小企業
  • 競合状況・動向

第12章 企業プロファイル

  • 主要企業
    • MICROSOFT
    • NVIDIA
    • EXSCIENTIA
    • GOOGLE
    • BENEVOLENTAI
    • NUMEDII, INC.
    • BERG, LLC
    • ATOMWISE
    • DEEP GENOMICS
    • INSILICO MEDICINE
    • SCHRODINGER, INC.
    • IBM
  • その他の企業
    • CYCLICA INC.
    • CLOUD PHARMACEUTICALS
    • BIOAGE
    • ENVISAGENICS
    • TWOXAR, INC. (ARIA PHARMACEUTICALS)
    • OWKIN, INC.
    • XTALPI, INC.
    • VERGE GENOMICS
    • IKTOS
    • EVAXION BIOTECH
    • STANDIGM
    • VALO HEALTH
    • BIOVISTA
    • BENCHSCI

第13章 付録

目次
Product Code: HIT 7445

The Artificial intelligence/AI in drug discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period. The growth of this market is primarily driven by factors such as the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications and services. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growt at certain extent over the forecast period. .

"Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period"

On the basis of offering, the AI in drug discovery market is bifurcated into software and services. the services segment expected to account for the largest market share of the global AI in drug discovery services market in 2022, and expected to grow fastest CAGR during the forecast period. The advantages and benefits associated with these services and the strong demand for AI services among end users are the key factors for thegrowth of this segment.

"Machine learning technology segment accounted for the largest share of the global AI in drug discovery market"

On the basis of technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. High adoption of machine learning technology among CRO, pharmaceutical and biotechnology companies and capability of these technologies to extract insights from data sets, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.

"Pharmaceutical & biotechnology companies segment expectd to hold the largest share of the market in 2022"

On the basis of end user, the AI in drug discovery market is divided into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. In 2021, the pharmaceutical & biotechnology companies segment accounted for the largest share of the AI in drug discovery market. On the other hand, research centers and academic & government institutes are expected to witness the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is the key growth factor of pharmaceutical and biotechnology end-user segment.

"North America to dominate the AI in drug discovery market in 2021"

The global AI in the drug discovery market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2021, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the major factors responsible for the large share and high growth rate of this market.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
  • By Designation: C-level (31%), Director-level (25%), and Others (44%)
  • By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (7%)

Prominent players in this market are NVIDIA Corporation (US), Microsoft Corporation (US), Google (US), Exscientia (UK), Schrodinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), BERG LLC (US), Cloud Pharmaceuticals (US), Insilico Medicine (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), Owkin, Inc. (US), XtalPi (US), Verge Genomics (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage

  • The report studies the AI in drug discovery market based on offering, technology, application, end user, and region
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
  • The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders
  • The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in drug discovery market
  • The report forecasts the revenue of market segments with respect to five major regions

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the AI in drug discovery market and provides them information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
  • 2.2 SECONDARY SOURCES
    • 2.2.1 KEY DATA FROM SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • 2.3.1 PRIMARY SOURCES
    • 2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
      • 2.3.2.1 Key industry insights
  • 2.4 MARKET SIZE ESTIMATION
    • FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY
    • TABLE 1 FACTOR ANALYSIS
    • FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE AI IN DRUG DISCOVERY MARKET (2022-2027)
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 8 TOP-DOWN APPROACH
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
    • TABLE 2 MARKET SIZING ASSUMPTIONS
  • 2.6 OVERALL STUDY ASSUMPTIONS
  • 2.7 LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET

4 PREMIUM INSIGHTS

  • 4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW
    • FIGURE 14 GROWING NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A KEY FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS
  • 4.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2021-2027)
    • FIGURE 15 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • 4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2021)
    • FIGURE 16 DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021
  • 4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Growing number of cross-industry collaborations and partnerships
    • TABLE 4 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2019-2021)
      • 5.2.1.2 Growing need to control drug discovery & development costs and reduce time involved in drug development
      • 5.2.1.3 Patent expiry of several drugs
    • TABLE 5 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2022
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Growing biotechnology industry
      • 5.2.3.2 Emerging markets
      • 5.2.3.3 Focus on developing human-aware AI systems
      • 5.2.3.4 Growth in the drugs and biologics market despite the COVID-19 pandemic
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Limited availability of data sets
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 19 AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS (2021)
  • 5.4 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 AI IN DRUG DISCOVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.5 ECOSYSTEM
    • FIGURE 20 AI IN DRUG DISCOVERY MARKET ECOSYSTEM
  • 5.6 TECHNOLOGY ANALYSIS
  • 5.7 PRICING ANALYSIS
  • 5.8 BUSINESS MODELS
    • FIGURE 21 AI IN LIFE SCIENCES: BUSINESS MODELS
    • FIGURE 22 BENEFITS OF HYBRID BUSINESS MODELS
    • FIGURE 23 SPECIALIZATION OF AI COMPANIES OVER TIME
  • 5.9 REGULATIONS
  • 5.10 CONFERENCES AND WEBINARS
  • 5.11 CASE STUDY ANALYSIS
    • 5.11.1 CASE STUDY 1
    • 5.11.2 CASE STUDY 2

6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING

  • 6.1 INTRODUCTION
    • TABLE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
  • 6.2 SOFTWARE
    • 6.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING SEGMENT GROWTH
    • TABLE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 9 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 10 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 SERVICES
    • 6.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
    • TABLE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 13 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 14 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)

7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 7.2 MACHINE LEARNING
    • TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 19 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 20 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 21 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.1 DEEP LEARNING
      • 7.2.1.1 Deep learning accelerates the discovery process of life-saving drugs and precision medicine
    • TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 25 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.2 SUPERVISED LEARNING
      • 7.2.2.1 Supervised learning can be applied in drug repositioning
    • TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 27 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 28 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 29 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.3 REINFORCEMENT LEARNING
      • 7.2.3.1 Insilico Medicine is a pioneer in the application of reinforcement learning in drug discovery
    • TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.4 UNSUPERVISED LEARNING
      • 7.2.4.1 Unsupervised learning can be more unpredictable than alternate models
    • TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
    • TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 OTHER TECHNOLOGIES
    • TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 43 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 44 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 45 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION)

8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.2 IMMUNO-ONCOLOGY
    • 8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH
    • TABLE 47 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT
    • TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 49 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 50 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 51 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 NEURODEGENERATIVE DISEASES
    • 8.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT
    • TABLE 52 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 53 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 54 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 55 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 CARDIOVASCULAR DISEASES
    • 8.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING SEGMENT GROWTH
    • TABLE 56 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
    • TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 58 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 59 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 60 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 METABOLIC DISEASES
    • 8.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT
    • TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 63 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 64 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.6 OTHER APPLICATIONS
    • TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 67 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 68 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAS DRAWN END-USER ATTENTION TO AI
    • TABLE 70 INDICATIVE LIST OF DEVELOPMENTS RELATED TO THE USE OF AI IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
    • TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 72 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 73 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 74 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.3 CONTRACT RESEARCH ORGANIZATIONS
    • 9.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS
    • TABLE 75 INDICATIVE LIST OF COLLABORATIONS WITH CROS
    • TABLE 76 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 77 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 78 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 79 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
    • 9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
    • TABLE 80 INDICATIVE LIST OF RESEARCH COLLABORATIONS
    • TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 83 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 84 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)

10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 24 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
    • TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Strong economy and trend of early adoption of technologies are driving market growth in the US
    • TABLE 91 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE US MARKET
    • TABLE 92 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 93 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 94 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 95 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Growing research on AI technologies and emergence of new AI-based start-ups will support market growth in Canada
    • TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.3 MEXICO
      • 10.2.3.1 Government initiatives to support market growth in Mexico
    • TABLE 100 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 101 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 102 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 103 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • FIGURE 25 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
    • TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.1 UK
      • 10.3.1.1 UK holds the largest share of the European market
    • TABLE 109 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE UK
    • TABLE 110 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 111 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Government support and favorable training programs are key market drivers in Germany
    • TABLE 114 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Strong government support and favorable strategies & initiatives to drive market growth in France
    • TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 119 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 120 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Presence of a strong pharmaceutical industry in Italy to drive market growth
    • TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.5 REST OF EUROPE
    • TABLE 126 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 127 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 128 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 129 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • TABLE 130 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 131 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 132 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 133 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 134 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Japan dominates the APAC market for AI in drug discovery
    • TABLE 135 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 136 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 137 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 138 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Growing CMO market and cross-industry collaborations are factors responsible for market growth in China
    • TABLE 139 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 140 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 141 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 142 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Steady adoption of AI technologies will drive market growth in India
    • TABLE 143 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 144 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 145 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 146 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 147 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 148 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 149 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 150 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • TABLE 151 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)
    • TABLE 152 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 153 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 154 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET
  • 11.3 MARKET RANKING ANALYSIS
    • TABLE 155 AI IN DRUG DISCOVERY MARKET RANKING ANALYSIS, BY KEY PLAYER, 2021
  • 11.4 COMPETITIVE BENCHMARKING
    • TABLE 156 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 157 AI IN DRUG DISCOVERY MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS
    • TABLE 158 AI IN DRUG DISCOVERY MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS
  • 11.5 COMPETITIVE LEADERSHIP MAPPING
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 26 AI IN DRUG DISCOVERY MARKET: GLOBAL COMPANY EVALUATION MATRIX, 2021
  • 11.6 COMPETITIVE LEADERSHIP MAPPING - START-UPS/SMES
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 27 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
  • 11.7 COMPETITIVE SITUATIONS AND TRENDS
    • TABLE 159 PRODUCT LAUNCHES
    • TABLE 160 DEALS

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **
  • 12.1 KEY PLAYERS
    • 12.1.1 MICROSOFT
    • TABLE 161 MICROSOFT: BUSINESS OVERVIEW
    • FIGURE 28 MICROSOFT: COMPANY SNAPSHOT (2020)
    • TABLE 162 MICROSOFT: DEALS
    • 12.1.2 NVIDIA
    • TABLE 163 NVIDIA: BUSINESS OVERVIEW
    • FIGURE 29 NVIDIA: COMPANY SNAPSHOT (2022)
    • TABLE 164 NVIDIA: EXPANSIONS
    • TABLE 165 NVIDIA: DEALS
    • 12.1.3 EXSCIENTIA
    • TABLE 166 EXSCIENTIA: BUSINESS OVERVIEW
    • FIGURE 30 EXSCIENTIA: COMPANY SNAPSHOT (2021)
    • 12.1.4 GOOGLE
    • TABLE 167 GOOGLE: BUSINESS OVERVIEW
    • FIGURE 31 GOOGLE: COMPANY SNAPSHOT (2021)
    • 12.1.5 BENEVOLENTAI
    • TABLE 168 BENEVOLENTAI: BUSINESS OVERVIEW
    • 12.1.6 NUMEDII, INC.
    • TABLE 169 NUMEDII: BUSINESS OVERVIEW
    • 12.1.7 BERG, LLC
    • TABLE 170 BERG, LLC: BUSINESS OVERVIEW
    • 12.1.8 ATOMWISE
    • TABLE 171 ATOMWISE: BUSINESS OVERVIEW
    • 12.1.9 DEEP GENOMICS
    • TABLE 172 DEEP GENOMICS: BUSINESS OVERVIEW
    • 12.1.10 INSILICO MEDICINE
    • TABLE 173 INSILICO MEDICINE: BUSINESS OVERVIEW
    • 12.1.11 SCHRODINGER, INC.
    • TABLE 174 SCHRODINGER: BUSINESS OVERVIEW
    • FIGURE 32 SCHRODINGER: COMPANY SNAPSHOT (2021)
    • 12.1.12 IBM
    • TABLE 175 IBM: BUSINESS OVERVIEW
    • FIGURE 33 IBM: COMPANY SNAPSHOT (2022)
    • TABLE 176 IBM: DEALS
    • TABLE 177 IBM: OTHER DEVELOPMENTS
  • 12.2 OTHER PLAYERS
    • 12.2.1 CYCLICA INC.
    • 12.2.2 CLOUD PHARMACEUTICALS
    • 12.2.3 BIOAGE
    • 12.2.4 ENVISAGENICS
    • 12.2.5 TWOXAR, INC. (ARIA PHARMACEUTICALS)
    • 12.2.6 OWKIN, INC.
    • 12.2.7 XTALPI, INC.
    • 12.2.8 VERGE GENOMICS
    • 12.2.9 IKTOS
    • 12.2.10 EVAXION BIOTECH
    • 12.2.11 STANDIGM
    • 12.2.12 VALO HEALTH
    • 12.2.13 BIOVISTA
    • 12.2.14 BENCHSCI
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS